Clinical outcomes after intravesical bacillus Calmette-Guérin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019.
Japanese Urological Association
bacillus Calmette-Guérin
highest risk
non-muscle-invasive bladder cancer
risk classification
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
20
06
2020
accepted:
14
02
2021
pubmed:
19
3
2021
medline:
28
7
2021
entrez:
18
3
2021
Statut:
ppublish
Résumé
To assess the clinical outcomes of highest-risk non-muscle-invasive bladder cancer patients treated with intravesical bacillus Calmette-Guérin. The medical charts of patients with non-muscle-invasive bladder cancer treated with intravesical bacillus Calmette-Guérin between 2000 and 2018 at a single institution were retrospectively reviewed. Patients were stratified into three groups (intermediate-, high- and highest-risk groups) according to the risk classification of the updated Japanese Urological Association guidelines 2019. Among the three groups, the intravesical recurrence-free survival and progression-free survival were estimated and compared, respectively. Furthermore, the different types of risk factors in the highest-risk group were analyzed. Of the 165 patients, 49 (30%) patients had intravesical recurrence and 23 (14%) patients showed progression to muscle-invasive disease during a median follow-up period of 53 months. Significant differences were not noted in the recurrence-free survival and progression-free survival among the three groups. Multivariable survival analysis of 74 patients in the highest-risk group showed that carcinoma in situ in the prostatic urethra was a significant predictor associated with recurrence (hazard ratio 3.20, P = 0.026) and progression (hazard ratio 4.36, P = 0.013). Intravesical bacillus Calmette-Guérin can control highest-risk non-muscle-invasive bladder cancer in most patients. Our findings might aid in decision-making regarding the treatment of this subset of patients who require intensive treatment, such as intravesical therapy with bacillus Calmette-Guérin and radical cystectomy.
Substances chimiques
Adjuvants, Immunologic
0
BCG Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
720-726Subventions
Organisme : JSPS KAKENHI
ID : 16K20159
Organisme : JSPS KAKENHI
ID : 26861290
Organisme : Fiscal Years 2015-2016 Nara Medical University Grant-in-Aid for Collaborative Research Projects
Informations de copyright
© 2021 The Japanese Urological Association.
Références
Moch H, Humphrey P, Ulbright T et al. WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th edn. IARCC Press, Lyon, 2016.
Kikuchi E, Fujimoto H, Mizutani Y et al. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from data on registered bladder cancer patients in Japan : 1999-2001 report from the Japanese Urological Association. Int. J. Urol. 2009; 16: 279-86.
Shelly MD, Mason MD, Kynaston H. intravesical therapy for superficial bladder cancer : a systematic review of randomized trials and meta-analyses. Cancer Treat Rev 2010; 36: 195-205.
Kamat AM, Sylvester RJ, Böhle A et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer : recommendations from the International Bladder Cancer Group. J. Clin. Oncol. 2016; 34: 1935-44.
Bochner BH. Optimal timing of radical cystectomy for patients with T1 bladder cancer. Urol. Oncol. 2009; 27: 3329-31.
Miyake M, Gotoh D, Fujimoto K et al. Exploration of risk factors predicting outcomes for primary T1 highgrade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long-term follow-up experience at a single institute. Int. J. Urol. 2015; 22: 541-7.
Nieder AM, Brausi M, Lamm D et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2005; 66(6 Suppl 1): 108-25.
Clark PE, Agarwal N, Biagioli MC et al. Bladder cancer. J. Natl Compr. Canc. Netw. 2013; 11: 446-75.
Nakai Y, Anai S, Tanaka N et al. Insignificant role of bacillus Calmette-Guerin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial. Int. J. Urol. 2016; 23: 854-60.
Wasco MJ, Daignault S, Zhang Y et al. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology 2007; 70: 69-74.
Gonzalez-Roibon ND, Chaux A, Al-Hussain T et al. Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder. Hum. Pathol. 2013; 44: 612-22.
Suh J, Moon KC, Jung JH et al. BCG instillation versus radical cystectomy for high-risk NMIBC with squamous/glandular histologic variants. Sci. Rep. 2019; 9: 152-68.
Brant A, Daniels M, Chappidi MR et al. Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer. World J. Urol. 2019; 12: 2683-9.
Palou J, Sylvester RJ, Faba OR et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. Eur. Urol. 2012; 62: 118-25.